nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES1—Capecitabine—esophageal cancer	0.461	0.924	CbGbCtD
Dabigatran etexilate—ABCB1—esophageal cancer	0.263	1	CbGaD
Dabigatran etexilate—ABCB1—Cisplatin—esophageal cancer	0.0228	0.0458	CbGbCtD
Dabigatran etexilate—ABCB1—Methotrexate—esophageal cancer	0.0148	0.0298	CbGbCtD
Dabigatran etexilate—CES1—larynx—esophageal cancer	0.0114	0.21	CbGeAlD
Dabigatran etexilate—Wound secretion—Capecitabine—esophageal cancer	0.00375	0.0635	CcSEcCtD
Dabigatran etexilate—F2—neck—esophageal cancer	0.0033	0.0607	CbGeAlD
Dabigatran etexilate—UGT2B15—digestive system—esophageal cancer	0.00311	0.0574	CbGeAlD
Dabigatran etexilate—CES1—neck—esophageal cancer	0.00303	0.0558	CbGeAlD
Dabigatran etexilate—Gastrointestinal ulcer—Methotrexate—esophageal cancer	0.00262	0.0443	CcSEcCtD
Dabigatran etexilate—CES2—bronchus—esophageal cancer	0.00246	0.0454	CbGeAlD
Dabigatran etexilate—CES2—smooth muscle tissue—esophageal cancer	0.00241	0.0444	CbGeAlD
Dabigatran etexilate—UGT1A9—digestive system—esophageal cancer	0.00236	0.0435	CbGeAlD
Dabigatran etexilate—F2—epithelium—esophageal cancer	0.00224	0.0413	CbGeAlD
Dabigatran etexilate—CES2—trachea—esophageal cancer	0.00221	0.0407	CbGeAlD
Dabigatran etexilate—NQO2—bronchus—esophageal cancer	0.0022	0.0405	CbGeAlD
Dabigatran etexilate—NQO2—trachea—esophageal cancer	0.00198	0.0364	CbGeAlD
Dabigatran etexilate—UGT2B7—digestive system—esophageal cancer	0.0019	0.035	CbGeAlD
Dabigatran etexilate—CES2—digestive system—esophageal cancer	0.0019	0.035	CbGeAlD
Dabigatran etexilate—Dyspnoea exertional—Capecitabine—esophageal cancer	0.0018	0.0305	CcSEcCtD
Dabigatran etexilate—F2—digestive system—esophageal cancer	0.00171	0.0314	CbGeAlD
Dabigatran etexilate—CES2—lung—esophageal cancer	0.00159	0.0293	CbGeAlD
Dabigatran etexilate—CES1—digestive system—esophageal cancer	0.00157	0.0289	CbGeAlD
Dabigatran etexilate—Oesophageal ulcer—Capecitabine—esophageal cancer	0.00149	0.0253	CcSEcCtD
Dabigatran etexilate—F2—lung—esophageal cancer	0.00143	0.0263	CbGeAlD
Dabigatran etexilate—NQO2—lung—esophageal cancer	0.00142	0.0262	CbGeAlD
Dabigatran etexilate—Drug hypersensitivity—Capecitabine—esophageal cancer	0.00135	0.0229	CcSEcCtD
Dabigatran etexilate—CES1—lung—esophageal cancer	0.00131	0.0241	CbGeAlD
Dabigatran etexilate—Haematocrit decreased—Methotrexate—esophageal cancer	0.00109	0.0184	CcSEcCtD
Dabigatran etexilate—CES2—lymph node—esophageal cancer	0.00109	0.02	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—esophageal cancer	0.000971	0.0179	CbGeAlD
Dabigatran etexilate—CES1—lymph node—esophageal cancer	0.000895	0.0165	CbGeAlD
Dabigatran etexilate—Infection—Carboplatin—esophageal cancer	0.000892	0.0151	CcSEcCtD
Dabigatran etexilate—Haematoma—Capecitabine—esophageal cancer	0.000866	0.0147	CcSEcCtD
Dabigatran etexilate—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000791	0.0134	CcSEcCtD
Dabigatran etexilate—Thrombosis—Capecitabine—esophageal cancer	0.000769	0.013	CcSEcCtD
Dabigatran etexilate—Haemoptysis—Capecitabine—esophageal cancer	0.000735	0.0124	CcSEcCtD
Dabigatran etexilate—Contusion—Capecitabine—esophageal cancer	0.000624	0.0106	CcSEcCtD
Dabigatran etexilate—Chest discomfort—Capecitabine—esophageal cancer	0.000615	0.0104	CcSEcCtD
Dabigatran etexilate—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.000602	0.0102	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Capecitabine—esophageal cancer	0.000602	0.0102	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000598	0.0101	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000591	0.01	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000575	0.00974	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000536	0.00907	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Capecitabine—esophageal cancer	0.000497	0.00842	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Capecitabine—esophageal cancer	0.000492	0.00833	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000483	0.00817	CcSEcCtD
Dabigatran etexilate—ABCB1—epithelium—esophageal cancer	0.000482	0.00889	CbGeAlD
Dabigatran etexilate—Nasopharyngitis—Cisplatin—esophageal cancer	0.000479	0.00811	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000452	0.00765	CcSEcCtD
Dabigatran etexilate—Bone disorder—Methotrexate—esophageal cancer	0.000448	0.00759	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000445	0.00754	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Cisplatin—esophageal cancer	0.000444	0.00752	CcSEcCtD
Dabigatran etexilate—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.000428	0.00725	CcSEcCtD
Dabigatran etexilate—ABCB1—trachea—esophageal cancer	0.000427	0.00786	CbGeAlD
Dabigatran etexilate—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000407	0.00689	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Cisplatin—esophageal cancer	0.000405	0.00685	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Capecitabine—esophageal cancer	0.000405	0.00685	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000395	0.00669	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Capecitabine—esophageal cancer	0.000395	0.00669	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Capecitabine—esophageal cancer	0.000395	0.00669	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000391	0.00661	CcSEcCtD
Dabigatran etexilate—ABCB1—digestive system—esophageal cancer	0.000367	0.00676	CbGeAlD
Dabigatran etexilate—Ecchymosis—Methotrexate—esophageal cancer	0.000366	0.0062	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Cisplatin—esophageal cancer	0.000366	0.0062	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Capecitabine—esophageal cancer	0.000365	0.00617	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Cisplatin—esophageal cancer	0.000364	0.00617	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Cisplatin—esophageal cancer	0.000363	0.00615	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Capecitabine—esophageal cancer	0.000361	0.00611	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000356	0.00602	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Capecitabine—esophageal cancer	0.000353	0.00598	CcSEcCtD
Dabigatran etexilate—Gastritis—Capecitabine—esophageal cancer	0.00035	0.00592	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000348	0.0059	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Cisplatin—esophageal cancer	0.000344	0.00582	CcSEcCtD
Dabigatran etexilate—Influenza—Capecitabine—esophageal cancer	0.000341	0.00578	CcSEcCtD
Dabigatran etexilate—Dysphagia—Capecitabine—esophageal cancer	0.000341	0.00578	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Capecitabine—esophageal cancer	0.000336	0.00569	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Cisplatin—esophageal cancer	0.000335	0.00567	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Cisplatin—esophageal cancer	0.000334	0.00566	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Capecitabine—esophageal cancer	0.000333	0.00563	CcSEcCtD
Dabigatran etexilate—Bronchitis—Capecitabine—esophageal cancer	0.000328	0.00556	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Capecitabine—esophageal cancer	0.000327	0.00554	CcSEcCtD
Dabigatran etexilate—Malnutrition—Cisplatin—esophageal cancer	0.000323	0.00546	CcSEcCtD
Dabigatran etexilate—Flatulence—Cisplatin—esophageal cancer	0.000318	0.00538	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000317	0.00537	CcSEcCtD
Dabigatran etexilate—ABCB1—lung—esophageal cancer	0.000306	0.00565	CbGeAlD
Dabigatran etexilate—Pneumonia—Capecitabine—esophageal cancer	0.000306	0.00518	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Capecitabine—esophageal cancer	0.000304	0.00515	CcSEcCtD
Dabigatran etexilate—Infestation—Capecitabine—esophageal cancer	0.000304	0.00515	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.0003	0.00508	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Capecitabine—esophageal cancer	0.000298	0.00505	CcSEcCtD
Dabigatran etexilate—Anaemia—Cisplatin—esophageal cancer	0.000298	0.00505	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Capecitabine—esophageal cancer	0.000296	0.00501	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Methotrexate—esophageal cancer	0.000294	0.00498	CcSEcCtD
Dabigatran etexilate—Haematuria—Capecitabine—esophageal cancer	0.00029	0.00491	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000288	0.00487	CcSEcCtD
Dabigatran etexilate—Epistaxis—Capecitabine—esophageal cancer	0.000287	0.00486	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Capecitabine—esophageal cancer	0.000275	0.00465	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Capecitabine—esophageal cancer	0.000273	0.00463	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000273	0.00462	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Methotrexate—esophageal cancer	0.000271	0.0046	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Capecitabine—esophageal cancer	0.00027	0.00457	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Capecitabine—esophageal cancer	0.000269	0.00456	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Capecitabine—esophageal cancer	0.000269	0.00455	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Capecitabine—esophageal cancer	0.000268	0.00454	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Cisplatin—esophageal cancer	0.000263	0.00446	CcSEcCtD
Dabigatran etexilate—Infection—Cisplatin—esophageal cancer	0.000262	0.00443	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Cisplatin—esophageal cancer	0.000258	0.00437	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Cisplatin—esophageal cancer	0.000258	0.00437	CcSEcCtD
Dabigatran etexilate—Skin disorder—Cisplatin—esophageal cancer	0.000256	0.00433	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Capecitabine—esophageal cancer	0.000254	0.00429	CcSEcCtD
Dabigatran etexilate—Angiopathy—Capecitabine—esophageal cancer	0.000248	0.0042	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Capecitabine—esophageal cancer	0.000247	0.00418	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Capecitabine—esophageal cancer	0.000246	0.00417	CcSEcCtD
Dabigatran etexilate—Hypotension—Cisplatin—esophageal cancer	0.000246	0.00417	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Methotrexate—esophageal cancer	0.000244	0.00412	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00024	0.00406	CcSEcCtD
Dabigatran etexilate—Malnutrition—Capecitabine—esophageal cancer	0.000238	0.00403	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000236	0.004	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Cisplatin—esophageal cancer	0.000235	0.00398	CcSEcCtD
Dabigatran etexilate—Flatulence—Capecitabine—esophageal cancer	0.000234	0.00397	CcSEcCtD
Dabigatran etexilate—Back pain—Capecitabine—esophageal cancer	0.00023	0.0039	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—esophageal cancer	0.000228	0.00386	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000227	0.00385	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—esophageal cancer	0.000227	0.00384	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—esophageal cancer	0.000227	0.00384	CcSEcCtD
Dabigatran etexilate—Anaemia—Capecitabine—esophageal cancer	0.00022	0.00372	CcSEcCtD
Dabigatran etexilate—Haematuria—Methotrexate—esophageal cancer	0.000216	0.00366	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000214	0.00363	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—esophageal cancer	0.000214	0.00362	CcSEcCtD
Dabigatran etexilate—Syncope—Capecitabine—esophageal cancer	0.000213	0.00361	CcSEcCtD
Dabigatran etexilate—Palpitations—Capecitabine—esophageal cancer	0.00021	0.00356	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—esophageal cancer	0.00021	0.00386	CbGeAlD
Dabigatran etexilate—Loss of consciousness—Capecitabine—esophageal cancer	0.000209	0.00354	CcSEcCtD
Dabigatran etexilate—Cough—Capecitabine—esophageal cancer	0.000208	0.00351	CcSEcCtD
Dabigatran etexilate—Hypertension—Capecitabine—esophageal cancer	0.000205	0.00348	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—esophageal cancer	0.000204	0.00346	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—esophageal cancer	0.000203	0.00344	CcSEcCtD
Dabigatran etexilate—Arthralgia—Capecitabine—esophageal cancer	0.000203	0.00343	CcSEcCtD
Dabigatran etexilate—Chest pain—Capecitabine—esophageal cancer	0.000203	0.00343	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000201	0.00341	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—esophageal cancer	0.000201	0.0034	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—esophageal cancer	0.000199	0.00338	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Cisplatin—esophageal cancer	0.000194	0.00329	CcSEcCtD
Dabigatran etexilate—Infection—Capecitabine—esophageal cancer	0.000193	0.00327	CcSEcCtD
Dabigatran etexilate—Shock—Capecitabine—esophageal cancer	0.000191	0.00323	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Capecitabine—esophageal cancer	0.00019	0.00322	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Capecitabine—esophageal cancer	0.00019	0.00322	CcSEcCtD
Dabigatran etexilate—Asthenia—Cisplatin—esophageal cancer	0.000189	0.0032	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—esophageal cancer	0.000189	0.0032	CcSEcCtD
Dabigatran etexilate—Skin disorder—Capecitabine—esophageal cancer	0.000189	0.00319	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—esophageal cancer	0.000185	0.00312	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—esophageal cancer	0.000184	0.00311	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000183	0.0031	CcSEcCtD
Dabigatran etexilate—Hypotension—Capecitabine—esophageal cancer	0.000181	0.00307	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Cisplatin—esophageal cancer	0.00018	0.00305	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—esophageal cancer	0.000177	0.003	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000177	0.00299	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Capecitabine—esophageal cancer	0.000173	0.00293	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—esophageal cancer	0.000171	0.0029	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Capecitabine—esophageal cancer	0.000171	0.00289	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000168	0.00284	CcSEcCtD
Dabigatran etexilate—Vomiting—Cisplatin—esophageal cancer	0.000167	0.00284	CcSEcCtD
Dabigatran etexilate—Fatigue—Capecitabine—esophageal cancer	0.000167	0.00283	CcSEcCtD
Dabigatran etexilate—Rash—Cisplatin—esophageal cancer	0.000166	0.00281	CcSEcCtD
Dabigatran etexilate—Constipation—Capecitabine—esophageal cancer	0.000166	0.00281	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cisplatin—esophageal cancer	0.000166	0.00281	CcSEcCtD
Dabigatran etexilate—Anaemia—Methotrexate—esophageal cancer	0.000164	0.00277	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000159	0.00269	CcSEcCtD
Dabigatran etexilate—Nausea—Cisplatin—esophageal cancer	0.000156	0.00265	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—esophageal cancer	0.000155	0.00262	CcSEcCtD
Dabigatran etexilate—Urticaria—Capecitabine—esophageal cancer	0.000154	0.00261	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Capecitabine—esophageal cancer	0.000153	0.0026	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—esophageal cancer	0.000151	0.00255	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—esophageal cancer	0.000151	0.00255	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00015	0.00253	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—esophageal cancer	0.000145	0.00245	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—esophageal cancer	0.000144	0.00243	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Capecitabine—esophageal cancer	0.000143	0.00242	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—esophageal cancer	0.000142	0.0024	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000141	0.0024	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—esophageal cancer	0.00014	0.00238	CcSEcCtD
Dabigatran etexilate—Asthenia—Capecitabine—esophageal cancer	0.000139	0.00236	CcSEcCtD
Dabigatran etexilate—Pruritus—Capecitabine—esophageal cancer	0.000137	0.00233	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—esophageal cancer	0.000135	0.00229	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Capecitabine—esophageal cancer	0.000133	0.00225	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000132	0.00223	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Methotrexate—esophageal cancer	0.000129	0.00218	CcSEcCtD
Dabigatran etexilate—Dizziness—Capecitabine—esophageal cancer	0.000128	0.00217	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—esophageal cancer	0.000127	0.00215	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000125	0.00211	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—esophageal cancer	0.000125	0.00211	CcSEcCtD
Dabigatran etexilate—Vomiting—Capecitabine—esophageal cancer	0.000123	0.00209	CcSEcCtD
Dabigatran etexilate—Rash—Capecitabine—esophageal cancer	0.000122	0.00207	CcSEcCtD
Dabigatran etexilate—Dermatitis—Capecitabine—esophageal cancer	0.000122	0.00207	CcSEcCtD
Dabigatran etexilate—Headache—Capecitabine—esophageal cancer	0.000122	0.00206	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000118	0.002	CcSEcCtD
Dabigatran etexilate—Nausea—Capecitabine—esophageal cancer	0.000115	0.00195	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—esophageal cancer	0.000115	0.00194	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—esophageal cancer	0.000114	0.00193	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—esophageal cancer	0.000106	0.0018	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL2—esophageal cancer	0.000104	0.000829	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—esophageal cancer	0.000104	0.000827	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Methotrexate—esophageal cancer	0.000104	0.00176	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TP53—esophageal cancer	0.000103	0.000818	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Methotrexate—esophageal cancer	0.000102	0.00173	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—GSTO1—esophageal cancer	0.000101	0.000803	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TPI1—esophageal cancer	0.000101	0.000803	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GDI2—esophageal cancer	9.9e-05	0.00079	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Methotrexate—esophageal cancer	9.89e-05	0.00167	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—ANXA1—esophageal cancer	9.66e-05	0.000771	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALDOB—esophageal cancer	9.65e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	9.64e-05	0.000769	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Methotrexate—esophageal cancer	9.56e-05	0.00162	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—SST—esophageal cancer	9.4e-05	0.00075	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GAPDH—esophageal cancer	9.29e-05	0.000741	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CRABP1—esophageal cancer	9.21e-05	0.000735	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Methotrexate—esophageal cancer	9.19e-05	0.00156	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—GHRL—esophageal cancer	9.16e-05	0.000731	CbGpPWpGaD
Dabigatran etexilate—Rash—Methotrexate—esophageal cancer	9.11e-05	0.00154	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—esophageal cancer	9.1e-05	0.00154	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—esophageal cancer	9.05e-05	0.00153	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	8.95e-05	0.000714	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.77e-05	0.0007	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GNG7—esophageal cancer	8.76e-05	0.000699	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HSPA5—esophageal cancer	8.6e-05	0.000686	CbGpPWpGaD
Dabigatran etexilate—Nausea—Methotrexate—esophageal cancer	8.58e-05	0.00145	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—BLVRB—esophageal cancer	8.37e-05	0.000668	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC52A3—esophageal cancer	8.37e-05	0.000668	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALDH2—esophageal cancer	8.21e-05	0.000655	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	8.15e-05	0.00065	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTT1—esophageal cancer	7.81e-05	0.000623	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP2A6—esophageal cancer	7.72e-05	0.000616	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKAP13—esophageal cancer	7.66e-05	0.000611	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—PIK3CA—esophageal cancer	7.66e-05	0.000611	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.65e-05	0.00061	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—ACTB—esophageal cancer	7.49e-05	0.000597	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS1—esophageal cancer	7.32e-05	0.000584	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ENO1—esophageal cancer	7.32e-05	0.000584	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	7.31e-05	0.000583	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—EP300—esophageal cancer	7.22e-05	0.000576	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PSME2—esophageal cancer	7.21e-05	0.000575	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PSME1—esophageal cancer	7.21e-05	0.000575	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KMT2D—esophageal cancer	7.16e-05	0.000571	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—esophageal cancer	7.15e-05	0.00057	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA1—esophageal cancer	7.12e-05	0.000568	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC10A2—esophageal cancer	7.12e-05	0.000568	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—esophageal cancer	7.06e-05	0.000563	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PDE4D—esophageal cancer	7.01e-05	0.000559	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKAP13—esophageal cancer	6.96e-05	0.000555	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC52A3—esophageal cancer	6.8e-05	0.000543	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BLVRB—esophageal cancer	6.8e-05	0.000543	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—HSPA5—esophageal cancer	6.77e-05	0.00054	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—GNG7—esophageal cancer	6.67e-05	0.000532	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CALR—esophageal cancer	6.56e-05	0.000523	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	6.55e-05	0.000522	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA2—esophageal cancer	6.51e-05	0.000519	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—GHRL—esophageal cancer	6.44e-05	0.000514	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADCYAP1—esophageal cancer	6.38e-05	0.000509	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ABL1—esophageal cancer	6.37e-05	0.000508	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PDE4D—esophageal cancer	6.37e-05	0.000508	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—esophageal cancer	6.37e-05	0.000508	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP8—esophageal cancer	6.36e-05	0.000508	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—FBXW7—esophageal cancer	6.34e-05	0.000506	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP1B1—esophageal cancer	6.22e-05	0.000496	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	6.08e-05	0.000485	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GNG7—esophageal cancer	6.06e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PLCE1—esophageal cancer	6.05e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ADH7—esophageal cancer	6.05e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	5.99e-05	0.000478	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL2—esophageal cancer	5.87e-05	0.000469	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP19A1—esophageal cancer	5.85e-05	0.000467	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—WWOX—esophageal cancer	5.84e-05	0.000466	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA1—esophageal cancer	5.78e-05	0.000461	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC10A2—esophageal cancer	5.78e-05	0.000461	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	5.7e-05	0.000455	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	5.66e-05	0.000452	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FKBP1A—esophageal cancer	5.55e-05	0.000443	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—esophageal cancer	5.53e-05	0.000441	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	5.51e-05	0.000439	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ANXA1—esophageal cancer	5.46e-05	0.000436	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—WIF1—esophageal cancer	5.43e-05	0.000433	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—HMOX1—esophageal cancer	5.34e-05	0.000426	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL2—esophageal cancer	5.33e-05	0.000426	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	5.33e-05	0.000425	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—SST—esophageal cancer	5.31e-05	0.000424	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ADH1B—esophageal cancer	5.31e-05	0.000423	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA2—esophageal cancer	5.29e-05	0.000422	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—GHRL—esophageal cancer	5.18e-05	0.000413	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.17e-05	0.000412	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ABCB1—esophageal cancer	5.12e-05	0.000409	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMP—esophageal cancer	5.07e-05	0.000405	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	5.05e-05	0.000403	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSNK1A1—esophageal cancer	5.01e-05	0.000399	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	4.98e-05	0.000397	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—ANXA1—esophageal cancer	4.96e-05	0.000396	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP26A1—esophageal cancer	4.93e-05	0.000393	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ADH7—esophageal cancer	4.92e-05	0.000392	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLCE1—esophageal cancer	4.92e-05	0.000392	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	4.87e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.86e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	4.83e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SST—esophageal cancer	4.82e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	4.82e-05	0.000384	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALOX15—esophageal cancer	4.81e-05	0.000383	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	4.75e-05	0.000379	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GHRL—esophageal cancer	4.7e-05	0.000375	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PFN1—esophageal cancer	4.68e-05	0.000374	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	4.68e-05	0.000373	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	4.62e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	4.62e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—esophageal cancer	4.61e-05	0.000367	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NOS2—esophageal cancer	4.59e-05	0.000366	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TPI1—esophageal cancer	4.59e-05	0.000366	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTO1—esophageal cancer	4.59e-05	0.000366	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	4.42e-05	0.000353	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALDOB—esophageal cancer	4.4e-05	0.000351	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ADH1B—esophageal cancer	4.31e-05	0.000344	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GAPDH—esophageal cancer	4.23e-05	0.000338	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ELMO1—esophageal cancer	4.21e-05	0.000336	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CRABP1—esophageal cancer	4.19e-05	0.000335	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—CREBBP—esophageal cancer	4.12e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMP—esophageal cancer	4.12e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	4.12e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKAP13—esophageal cancer	4.11e-05	0.000328	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	4.03e-05	0.000322	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP26A1—esophageal cancer	4.01e-05	0.00032	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GNG7—esophageal cancer	3.99e-05	0.000318	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALOX15—esophageal cancer	3.91e-05	0.000312	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIST1H2BM—esophageal cancer	3.79e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDE4D—esophageal cancer	3.76e-05	0.0003	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALDH2—esophageal cancer	3.74e-05	0.000298	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TPI1—esophageal cancer	3.73e-05	0.000297	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTO1—esophageal cancer	3.73e-05	0.000297	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NOS3—esophageal cancer	3.69e-05	0.000295	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GNG7—esophageal cancer	3.58e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALDOB—esophageal cancer	3.57e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTT1—esophageal cancer	3.56e-05	0.000284	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP2A6—esophageal cancer	3.52e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	3.5e-05	0.000279	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GAPDH—esophageal cancer	3.44e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CREBBP—esophageal cancer	3.42e-05	0.000273	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CRABP1—esophageal cancer	3.41e-05	0.000272	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—XIAP—esophageal cancer	3.35e-05	0.000267	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS1—esophageal cancer	3.33e-05	0.000266	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO1—esophageal cancer	3.33e-05	0.000266	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSME1—esophageal cancer	3.28e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSME2—esophageal cancer	3.28e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GNG7—esophageal cancer	3.24e-05	0.000259	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	3.18e-05	0.000253	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNA1—esophageal cancer	3.17e-05	0.000253	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL2—esophageal cancer	3.15e-05	0.000251	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	3.14e-05	0.00025	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	3.13e-05	0.000249	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC52A3—esophageal cancer	3.12e-05	0.000249	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BLVRB—esophageal cancer	3.12e-05	0.000249	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NOS3—esophageal cancer	3.07e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALDH2—esophageal cancer	3.04e-05	0.000242	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSME1—esophageal cancer	2.94e-05	0.000235	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSME2—esophageal cancer	2.94e-05	0.000235	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ANXA1—esophageal cancer	2.93e-05	0.000234	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTT1—esophageal cancer	2.89e-05	0.00023	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP2A6—esophageal cancer	2.86e-05	0.000228	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SST—esophageal cancer	2.85e-05	0.000227	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.85e-05	0.000227	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1B1—esophageal cancer	2.83e-05	0.000226	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—esophageal cancer	2.81e-05	0.000224	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—esophageal cancer	2.8e-05	0.000224	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GHRL—esophageal cancer	2.78e-05	0.000222	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH3—esophageal cancer	2.78e-05	0.000222	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FBXW7—esophageal cancer	2.73e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO1—esophageal cancer	2.71e-05	0.000216	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS1—esophageal cancer	2.71e-05	0.000216	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.69e-05	0.000215	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSME2—esophageal cancer	2.67e-05	0.000213	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSME1—esophageal cancer	2.67e-05	0.000213	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP19A1—esophageal cancer	2.66e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA1—esophageal cancer	2.65e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC10A2—esophageal cancer	2.65e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.62e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.56e-05	0.000204	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH2—esophageal cancer	2.49e-05	0.000199	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HMOX1—esophageal cancer	2.43e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA2—esophageal cancer	2.43e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—esophageal cancer	2.33e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—esophageal cancer	2.33e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.33e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.31e-05	0.000184	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1B1—esophageal cancer	2.3e-05	0.000184	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLCE1—esophageal cancer	2.26e-05	0.00018	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADH7—esophageal cancer	2.26e-05	0.00018	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.24e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFBR2—esophageal cancer	2.21e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP19A1—esophageal cancer	2.16e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.13e-05	0.00017	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMAD4—esophageal cancer	2.09e-05	0.000167	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—esophageal cancer	2.08e-05	0.000166	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—esophageal cancer	2.01e-05	0.00016	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADH1B—esophageal cancer	1.98e-05	0.000158	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HMOX1—esophageal cancer	1.98e-05	0.000158	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.94e-05	0.000155	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.93e-05	0.000154	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—esophageal cancer	1.9e-05	0.000151	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMP—esophageal cancer	1.89e-05	0.000151	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.86e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.84e-05	0.000147	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.81e-05	0.000145	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALOX15—esophageal cancer	1.79e-05	0.000143	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—esophageal cancer	1.72e-05	0.000138	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—esophageal cancer	1.71e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTO1—esophageal cancer	1.71e-05	0.000136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TPI1—esophageal cancer	1.71e-05	0.000136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDOB—esophageal cancer	1.64e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—esophageal cancer	1.64e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GAPDH—esophageal cancer	1.58e-05	0.000126	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.57e-05	0.000126	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CRABP1—esophageal cancer	1.56e-05	0.000125	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CREBBP—esophageal cancer	1.56e-05	0.000124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH1—esophageal cancer	1.54e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.52e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNG7—esophageal cancer	1.49e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.43e-05	0.000114	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CREBBP—esophageal cancer	1.4e-05	0.000112	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NOS3—esophageal cancer	1.4e-05	0.000111	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDH2—esophageal cancer	1.39e-05	0.000111	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—esophageal cancer	1.37e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—esophageal cancer	1.33e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.31e-05	0.000105	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.31e-05	0.000105	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—esophageal cancer	1.28e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CREBBP—esophageal cancer	1.27e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOS3—esophageal cancer	1.25e-05	9.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS1—esophageal cancer	1.24e-05	9.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO1—esophageal cancer	1.24e-05	9.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.24e-05	9.9e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSME2—esophageal cancer	1.22e-05	9.76e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSME1—esophageal cancer	1.22e-05	9.76e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—esophageal cancer	1.19e-05	9.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—esophageal cancer	1.17e-05	9.34e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NOS3—esophageal cancer	1.13e-05	9.05e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—esophageal cancer	1.06e-05	8.47e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.06e-05	8.42e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—esophageal cancer	1.04e-05	8.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—esophageal cancer	1.03e-05	8.25e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—esophageal cancer	1e-05	7.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP19A1—esophageal cancer	9.93e-06	7.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—esophageal cancer	9.52e-06	7.6e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMOX1—esophageal cancer	9.06e-06	7.23e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—esophageal cancer	8.63e-06	6.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—esophageal cancer	8.3e-06	6.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—esophageal cancer	8.12e-06	6.47e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—esophageal cancer	7.86e-06	6.27e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—esophageal cancer	7.04e-06	5.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—esophageal cancer	6.81e-06	5.44e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—esophageal cancer	6.38e-06	5.09e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CREBBP—esophageal cancer	5.81e-06	4.64e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NOS3—esophageal cancer	5.2e-06	4.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—esophageal cancer	4.76e-06	3.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—esophageal cancer	3.96e-06	3.16e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.93e-06	2.34e-05	CbGpPWpGaD
